Advaxis, Inc. (ADXS) Holdings Boosted by Schwab Charles Investment Management Inc.

Schwab Charles Investment Management Inc. boosted its holdings in shares of Advaxis, Inc. (NASDAQ:ADXS) by 0.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 129,321 shares of the biotechnology company’s stock after buying an additional 817 shares during the quarter. Schwab Charles Investment Management Inc. owned approximately 0.32% of Advaxis worth $840,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. FMR LLC increased its position in Advaxis by 4.5% during the first quarter. FMR LLC now owns 4,287,780 shares of the biotechnology company’s stock worth $35,031,000 after buying an additional 184,895 shares during the last quarter. Vanguard Group Inc. increased its position in Advaxis by 9.2% during the first quarter. Vanguard Group Inc. now owns 1,663,010 shares of the biotechnology company’s stock worth $13,587,000 after buying an additional 139,710 shares during the last quarter. Geode Capital Management LLC increased its position in Advaxis by 4.8% during the first quarter. Geode Capital Management LLC now owns 279,812 shares of the biotechnology company’s stock worth $2,286,000 after buying an additional 12,736 shares during the last quarter. Bank of New York Mellon Corp increased its position in Advaxis by 1.9% during the first quarter. Bank of New York Mellon Corp now owns 183,788 shares of the biotechnology company’s stock worth $1,501,000 after buying an additional 3,462 shares during the last quarter. Finally, Parametric Portfolio Associates LLC increased its position in Advaxis by 116.3% during the first quarter. Parametric Portfolio Associates LLC now owns 86,586 shares of the biotechnology company’s stock worth $707,000 after buying an additional 46,559 shares during the last quarter. 48.02% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Advaxis, Inc. (NASDAQ:ADXS) opened at 3.40 on Wednesday. The stock’s 50 day moving average price is $4.21 and its 200-day moving average price is $6.44. Advaxis, Inc. has a one year low of $3.04 and a one year high of $10.88. The company’s market cap is $139.62 million.

Advaxis (NASDAQ:ADXS) last issued its quarterly earnings results on Monday, September 11th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.27). Advaxis had a negative return on equity of 93.54% and a negative net margin of 655.66%. The company had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $3.43 million. On average, analysts expect that Advaxis, Inc. will post ($2.23) EPS for the current year.

In other news, major shareholder Adage Capital Partners Gp, L.L sold 600,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 11th. The shares were sold at an average price of $4.30, for a total transaction of $2,580,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 7.21% of the company’s stock.

ADXS has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $23.00 price target on shares of Advaxis in a research report on Friday, September 15th. BidaskClub downgraded Advaxis from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. ValuEngine downgraded Advaxis from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 8th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $19.00 price target on shares of Advaxis in a research report on Monday, September 25th.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.com-unik.info/2017/11/01/advaxis-inc-adxs-holdings-boosted-by-schwab-charles-investment-management-inc.html.

Advaxis Company Profile

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Want to see what other hedge funds are holding ADXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Advaxis, Inc. (NASDAQ:ADXS).

Institutional Ownership by Quarter for Advaxis (NASDAQ:ADXS)

What are top analysts saying about Advaxis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Advaxis Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit